RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc
← Directory

Protocol Single compound

Melanotan II

MT-II

Cyclic melanocortin analog referenced in melanocortin receptor research.

Compare side by side →

Compared with:PT-141 vs Melanotan II

Cognitive

Laboratory reference · in vitro research data

Research vial sizes
10 mg
Dosing data
Not listed — reference entry covers vial concentration only.
Storage
Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.

Reconstitution concentrations

Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.

VialBAC watermg/mLmg per 10 u
10 mg1 mL101
10 mg2 mL50.5
10 mg3 mL3.330.333

Calculate your vial

Add reminder

Enter your own schedule. Saved only on this device — never sent anywhere.

Research use only — educational reference, not medical advice. This line is added to every reminder.

Works with iPhone Calendar, Google Calendar and Outlook.

Saved only in this browser. My reminders

Inputs
mg
mL
1 mg = 1,000 mcg
mg

Draw to

—units

= — mL on a U-100 syringe

Concentration
—
Per unit
—
Doses / vial
—
Syringe
01020304050607080901000.0u
U-100 · 100 units (1 mL)2 unit per line

Research dossier · published literature summary

01

Mechanism of action

Melanotan II is a non-selective melanocortin receptor agonist. MC1 activity increases melanin (tanning); central melanocortin activity produces erections and sexual stimulation.

02

Observed research endpoints

  • An early phase 1 study in healthy men reported increased facial and body pigmentation, spontaneous erections, nausea, and a stretching and yawning complex.
  • A qualitative study of 623 online forum entries found use driven by tanning goals, frequent misinformation and concerning practices with unregulated products.

03

Regulatory & safety context

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Case reports link unregulated use to rhabdomyolysis, kidney failure and renal infarction.

04

Citations

  1. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–1784.1996Phase 1 clinical studyRead paper ↗
  2. Peters B, et al. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159–161.2020Case report and literature reviewRead paper ↗
  3. Gilhooley E, et al. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology. 2021;237:995–999.2021Qualitative studyRead paper ↗

Keep exploring

Head-to-head articles

Where researchers source it

Listings are provided for reference — always verify the latest third-party COA before purchasing.

Medvinci Research

See site

Featured supplier · third-party tested, COA published per batch

View product View COA

Supplier B

TBD

Placeholder — details coming soon

View productView COA

Supplier C

TBD

Placeholder — details coming soon

View productView COA